Tarsus Pharmaceuticals, Inc. (TARS) compared with its closest peers (ADPT, IOVA, DNLI, RLAY, BEAM). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Adaptive Biotechnologies Corporation (ADPT) | $4.07B | -41.6 |
| Iovance Biotherapeutics, Inc. (IOVA) | $4.05B | -2.5 |
| Denali Therapeutics Inc. (DNLI) | $3.99B | -5.6 |
| Relay Therapeutics, Inc. (RLAY) | $3.78B | -5.3 |
| Beam Therapeutics Inc. (BEAM) | $2.93B | -34.2 |
| Kodiak Sciences Inc. (KOD) | $2.50B | -6.5 |
| BioCryst Pharmaceuticals, Inc. (BCRX) | $2.47B | 6.5 |
| ADMA Biologics, Inc. (ADMA) | $2.26B | 13.7 |
| Hemab Therapeutics Holdings, Inc. (COAG) | $2.25B | — |
| Vericel Corporation (VCEL) | $2.15B | 112.5 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
TARS overview · TARS earnings · TARS financials · TARS KPIs · TARS investor relations · TARS ownership · TARS filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.